JP2019527066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527066A5 JP2019527066A5 JP2019514203A JP2019514203A JP2019527066A5 JP 2019527066 A5 JP2019527066 A5 JP 2019527066A5 JP 2019514203 A JP2019514203 A JP 2019514203A JP 2019514203 A JP2019514203 A JP 2019514203A JP 2019527066 A5 JP2019527066 A5 JP 2019527066A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- item
- naturally occurring
- peptide
- synthetic peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 38
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 102000002490 Rad51 Recombinase Human genes 0.000 claims description 13
- 108010068097 Rad51 Recombinase Proteins 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 101000620735 Homo sapiens DNA repair protein RAD51 homolog 1 Proteins 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 102000051623 human RAD51 Human genes 0.000 claims description 10
- 102100031535 RAD51-associated protein 1 Human genes 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 108091006112 ATPases Proteins 0.000 claims description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000006801 homologous recombination Effects 0.000 claims description 2
- 238000002744 homologous recombination Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 101710182832 RAD51-associated protein 1 Proteins 0.000 claims 2
- 230000021736 acetylation Effects 0.000 claims 2
- 238000006640 acetylation reaction Methods 0.000 claims 2
- 230000009435 amidation Effects 0.000 claims 2
- 238000007112 amidation reaction Methods 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 42
- 238000000034 method Methods 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 239000013600 plasmid vector Substances 0.000 description 13
- 230000004568 DNA-binding Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 102000018120 Recombinases Human genes 0.000 description 7
- 108010091086 Recombinases Proteins 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 108020005345 3' Untranslated Regions Proteins 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 101001130243 Homo sapiens RAD51-associated protein 1 Proteins 0.000 description 4
- 101710096444 Killer toxin Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 108030001740 Anthrax lethal factor endopeptidases Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 208000005692 Bloom Syndrome Diseases 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101800000891 Phallacidin Proteins 0.000 description 1
- 101100152717 Psittacid herpesvirus 1 (isolate Amazon parrot/-/97-0001/1997) sORF1 gene Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 101000616303 Saccharomyces cerevisiae killer virus M1 M1-1 protoxin Proteins 0.000 description 1
- 108010079723 Shiga Toxin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- KUBDTFZQCYLLGC-VZORSVKHSA-N phallacidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KUBDTFZQCYLLGC-VZORSVKHSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084997A JP7479421B2 (ja) | 2016-05-27 | 2022-05-25 | タンパク質界面 |
| JP2024070016A JP2024099695A (ja) | 2016-05-27 | 2024-04-23 | タンパク質界面 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342840P | 2016-05-27 | 2016-05-27 | |
| US62/342,840 | 2016-05-27 | ||
| US201662384226P | 2016-09-07 | 2016-09-07 | |
| US62/384,226 | 2016-09-07 | ||
| PCT/US2017/034870 WO2017205852A2 (en) | 2016-05-27 | 2017-05-26 | Protein interfaces |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084997A Division JP7479421B2 (ja) | 2016-05-27 | 2022-05-25 | タンパク質界面 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527066A JP2019527066A (ja) | 2019-09-26 |
| JP2019527066A5 true JP2019527066A5 (enExample) | 2020-07-02 |
| JP7080878B2 JP7080878B2 (ja) | 2022-06-06 |
Family
ID=60411842
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514203A Active JP7080878B2 (ja) | 2016-05-27 | 2017-05-26 | タンパク質界面 |
| JP2022084997A Active JP7479421B2 (ja) | 2016-05-27 | 2022-05-25 | タンパク質界面 |
| JP2024070016A Pending JP2024099695A (ja) | 2016-05-27 | 2024-04-23 | タンパク質界面 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084997A Active JP7479421B2 (ja) | 2016-05-27 | 2022-05-25 | タンパク質界面 |
| JP2024070016A Pending JP2024099695A (ja) | 2016-05-27 | 2024-04-23 | タンパク質界面 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10188691B2 (enExample) |
| EP (2) | EP3463414B1 (enExample) |
| JP (3) | JP7080878B2 (enExample) |
| CN (2) | CN109562138B (enExample) |
| AU (4) | AU2017271678B2 (enExample) |
| BR (1) | BR112018074472A2 (enExample) |
| CA (1) | CA3025423A1 (enExample) |
| MX (2) | MX2018014366A (enExample) |
| WO (1) | WO2017205852A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3025423A1 (en) | 2016-05-27 | 2017-11-30 | Synthex, Inc. | Protein interfaces |
| WO2019099678A1 (en) | 2017-11-16 | 2019-05-23 | Synthex, Inc. | Selective modulation of protein-protein interactions |
| GB2584210B (en) * | 2017-11-22 | 2022-03-16 | Synthex Inc | Peptides for inhibiting RAD51 |
| WO2020223601A1 (en) * | 2019-05-01 | 2020-11-05 | Innate Biologics Llc | Immunomodulatory compositions and methods |
| AU2020275425B2 (en) | 2019-05-15 | 2024-06-27 | Synthex, Inc. | Selective degradation of proteins |
| JP2023145812A (ja) * | 2020-08-17 | 2023-10-12 | 国立大学法人東海国立大学機構 | 人工タンパク質、Ｒａｓ阻害剤及び抗がん剤 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
| US5733726A (en) | 1995-06-07 | 1998-03-31 | Emory University | Cytotoxicity-based genetic selection system (TOXSEL) |
| WO1998007845A1 (en) | 1996-08-23 | 1998-02-26 | President And Fellows Of Harvard College | Interaction trap assay, reagents and uses thereof |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| US6037125A (en) | 1996-11-05 | 2000-03-14 | Lexicon Genetics Incorporated | Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells |
| CZ20001841A3 (cs) | 1997-11-19 | 2001-09-12 | Microbia, Inc. | Chimérní preaktivované transkripční faktory |
| US6303302B1 (en) | 1997-11-19 | 2001-10-16 | The Whitehead Institute For Biomedical Research | Regulation of fungal gene expression |
| CA2417135C (en) | 1997-11-19 | 2005-04-12 | Microbia, Inc. | Chimeric pre-activated transcription factors |
| US6610495B1 (en) | 1998-01-09 | 2003-08-26 | Tvw Telethon Intstitute For Child Health Research | Method for detecting proteinaceous inhibitors of protein-protein or DNA-protein interactions |
| US6332897B1 (en) | 1998-03-27 | 2001-12-25 | Glaxo Wellcome Inc. | Assay methods |
| ES2284245T3 (es) | 1998-03-26 | 2007-11-01 | Glaxo Group Limited | Metodo para detectar interaccion proteina-proteina. |
| US6316223B1 (en) | 1998-03-30 | 2001-11-13 | Rigel Pharmaceuticals, Inc. | Mammalian protein interaction cloning system |
| US6114111A (en) | 1998-03-30 | 2000-09-05 | Rigel Pharmaceuticals, Inc. | Mammalian protein interaction cloning system |
| DE19901008A1 (de) * | 1999-01-13 | 2000-07-20 | Deutsches Krebsforsch | Peptide zur Inhibierung von HPV E6-Proteinen |
| AU3733100A (en) | 1999-03-09 | 2000-09-28 | Lexicon Genetics Incorporated | Compounds that disrupt mammalian rad51 activity |
| US7270969B2 (en) * | 1999-05-05 | 2007-09-18 | Phylogica Limited | Methods of constructing and screening diverse expression libraries |
| AU783233B2 (en) | 1999-06-07 | 2005-10-06 | Tet Systems Holding Gmbh & Co. Kg | Novel TET repressor-based transcriptional regulatory proteins |
| AU1074401A (en) | 1999-10-07 | 2001-05-10 | Genetic Technologies, L.P. | Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis |
| US6790607B1 (en) | 1999-10-07 | 2004-09-14 | Hybrigen, Inc. | Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis |
| US20020086840A1 (en) | 2000-01-26 | 2002-07-04 | Zarling David A. | Use of Rad51 inhibitors for p53 gene therapy |
| WO2001066565A2 (en) | 2000-03-06 | 2001-09-13 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides |
| US7378248B2 (en) | 2000-03-06 | 2008-05-27 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides for inhibiting protein-protein interaction |
| US7566765B2 (en) | 2000-03-06 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Heterocyclic compounds containing a nine-membered carbon-nitrogen ring |
| US7252952B2 (en) | 2000-03-06 | 2007-08-07 | Rigel Pharmaceuticals, Inc. | In vivo production of cyclic peptides for inhibiting protein—protein interaction |
| US20030211495A1 (en) | 2000-03-08 | 2003-11-13 | Richard Hopkins | Reverse n-hybrid screening method |
| CA2402111A1 (en) | 2000-03-08 | 2001-09-13 | Tvw Telethon Institute For Child Health Research | Improved reverse n-hybrid screening method |
| AU2001245584B2 (en) | 2000-03-08 | 2007-02-08 | Phylogica Limited | Improved reverse n-hybrid screening method |
| GB0006572D0 (en) | 2000-03-17 | 2000-05-10 | Isis Innovation | Novel transcription transactivator protein |
| WO2003013488A2 (en) | 2001-08-09 | 2003-02-20 | Pangene Corporation | Methods and compositions for inhibiting rad51 |
| US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
| WO2004042064A2 (en) * | 2002-11-07 | 2004-05-21 | Imperial College Innovations Limited | Disorders of lipid metabolism |
| JP2004215624A (ja) * | 2003-01-17 | 2004-08-05 | Celestar Lexico-Sciences Inc | 相互作用インヒビターの検出方法、相互作用インヒビターライブラリーおよびインヒビター検出キット |
| ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
| US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
| JP2005095613A (ja) | 2003-09-04 | 2005-04-14 | Taiyo Parts Kk | 昇降装置 |
| CN1905864B (zh) * | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| JPWO2005095613A1 (ja) | 2004-03-30 | 2008-02-21 | ジェノミディア株式会社 | Ｒａｄ５１の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用 |
| US20060116316A1 (en) | 2004-10-14 | 2006-06-01 | Kinsella Todd M | Heterocyclic inhibitors of IRES-mediated translation and methods of use thereof |
| EP2626067A1 (en) | 2006-12-26 | 2013-08-14 | Pharmacyclics, Inc. | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| US7892823B2 (en) | 2007-02-06 | 2011-02-22 | Geneprotech, Inc. | Methods and systems for high homologous recombination (“HR”) targeting efficiency |
| US8759089B2 (en) | 2007-02-06 | 2014-06-24 | Geneprotech, Inc. | Methods and systems for high homologous recombination (“HR”) targeting efficiency |
| US8105493B2 (en) | 2007-06-29 | 2012-01-31 | Jnc Corporation | Aggregation and dispersion methods of magnetic particles, separation and detection methods using the same and detection kit |
| US8597949B2 (en) * | 2007-07-28 | 2013-12-03 | The University Of Chicago | Methods and compositions for modulating RAD51 and homologous recombination |
| US9518097B2 (en) | 2007-11-09 | 2016-12-13 | Board Of Trustees Of Michigan State University | Identification and use of genes encoding amatoxin and phallotoxin |
| US9273100B2 (en) | 2007-11-09 | 2016-03-01 | Board Of Trustees Of Michigan State University | Use of Galerina marginata genes and proteins for peptide production |
| US9150897B2 (en) | 2010-08-06 | 2015-10-06 | The Regents Of The University Of California | Expression and purification of fusion protein with multiple MBP tags |
| US9249410B2 (en) | 2010-12-15 | 2016-02-02 | The Johns Hopkins University | Two-hybrid based screen to identify disruptive residues at multiple protein interfaces |
| US10912761B2 (en) | 2012-11-30 | 2021-02-09 | The University Of Chicago | Methods and compositions involving RAD51 inhibitors |
| WO2015138377A1 (en) | 2014-03-10 | 2015-09-17 | The University Of Chicago | Methods of treating cancer using rad51small molecule stimulators |
| US10421753B2 (en) | 2015-03-02 | 2019-09-24 | The Regents Of The University Of California | RAD51 inhibitors and uses thereof |
| CA3025423A1 (en) | 2016-05-27 | 2017-11-30 | Synthex, Inc. | Protein interfaces |
| WO2019099678A1 (en) | 2017-11-16 | 2019-05-23 | Synthex, Inc. | Selective modulation of protein-protein interactions |
-
2017
- 2017-05-26 CA CA3025423A patent/CA3025423A1/en active Pending
- 2017-05-26 BR BR112018074472-7A patent/BR112018074472A2/pt active Search and Examination
- 2017-05-26 JP JP2019514203A patent/JP7080878B2/ja active Active
- 2017-05-26 EP EP17803737.0A patent/EP3463414B1/en active Active
- 2017-05-26 WO PCT/US2017/034870 patent/WO2017205852A2/en not_active Ceased
- 2017-05-26 AU AU2017271678A patent/AU2017271678B2/en active Active
- 2017-05-26 CN CN201780046940.6A patent/CN109562138B/zh active Active
- 2017-05-26 CN CN202310203866.1A patent/CN116217657A/zh active Pending
- 2017-05-26 EP EP23188944.5A patent/EP4269427A3/en active Pending
- 2017-05-26 MX MX2018014366A patent/MX2018014366A/es unknown
- 2017-08-22 US US15/683,586 patent/US10188691B2/en active Active
-
2018
- 2018-11-22 MX MX2023002591A patent/MX2023002591A/es unknown
- 2018-12-10 US US16/215,432 patent/US20190216879A1/en not_active Abandoned
-
2021
- 2021-02-09 US US17/171,841 patent/US12214008B2/en active Active
- 2021-07-13 AU AU2021205010A patent/AU2021205010B2/en active Active
-
2022
- 2022-05-25 JP JP2022084997A patent/JP7479421B2/ja active Active
- 2022-10-24 AU AU2022259709A patent/AU2022259709A1/en not_active Abandoned
-
2024
- 2024-04-23 JP JP2024070016A patent/JP2024099695A/ja active Pending
- 2024-06-26 AU AU2024204362A patent/AU2024204362A1/en active Pending
- 2024-12-10 US US18/975,990 patent/US20250177474A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527066A5 (enExample) | ||
| Harada et al. | Selection of RNA-binding peptides in vivo | |
| Salomone et al. | A novel chimeric cell-penetrating peptide with membrane-disruptive properties for efficient endosomal escape | |
| EP3268023B1 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
| Kayal et al. | Listeriolysin O: a key protein of Listeria monocytogenes with multiple functions | |
| AU2017201163B2 (en) | Method of determining, identifying or isolating cell-penetrating peptides | |
| Bieler et al. | Bactericidal activity of both secreted and nonsecreted microcin E492 requires the mannose permease | |
| AU2020256311B2 (en) | ATF5 peptide variants and uses thereof | |
| EP3066113A2 (en) | Peptide inhibitors of tead/yap-taz interaction | |
| RS62047B1 (sr) | Imunosupresivni agensi i njihova upotreba u terapiji | |
| CA2906572A1 (en) | Stabilized ezh2 peptides | |
| NZ708990A (en) | Method for activating helper t cell | |
| EP2688904A1 (en) | Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy | |
| JP2023547405A (ja) | Ｃａｓ９－ＲＮＰ及び他の核タンパク質カーゴの形質導入のために適合された最小長のシャトル剤ペプチド及びそのバリアント | |
| Yang et al. | A dopamine-responsive signal transduction controls transcription of salmonella enterica Serovar Typhimurium virulence genes | |
| WO2020109864A1 (en) | Dpep-1 binding agents and methods of use | |
| JP2019108277A5 (enExample) | ||
| US8440788B2 (en) | N-terminal VDAC variants and uses thereof | |
| JP2021531246A (ja) | ペプチド化合物およびその治療的用途 | |
| ES2941467T3 (es) | Tratamiento de una enfermedad asociada a la infección por una bacteria oncogénica | |
| DK2578227T3 (en) | METHOD OF CANCER THERAPY | |
| WO2022069557A3 (en) | Amidated peptides and their deamidated counterparts displayed by hla-a*02 for use in immunotherapy against different types of cancers | |
| Male | Identification of inhibitors of protein-protein interactions essential for virulence in pathogenic bacteria | |
| WO2022069579A3 (en) | Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancers | |
| HK1249033B (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection |